Labcorp (LH) FY2024 10-K Annual Report
Labcorp (LH) 10-K annual report for fiscal year 2024, filed with SEC EDGAR on Feb 25, 2025. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Labcorp FY2024 10-K Analysis
Business Overview
- • Core business model: Global comprehensive laboratory services providing diagnostic and drug development insights to healthcare and pharmaceutical clients across ~100 countries
- • New holding company structure implemented May 17, 2024, establishing Labcorp Holdings Inc. as successor issuer with no independent operations
Management Discussion & Analysis
- • Revenue $13,008.9M, up 7.0% YoY from $12,161.6M; Dx segment $10,144.3M up 7.7%, BLS $2,922.6M up 5.3%
- • Operating margin Dx 15.8% vs 16.9% (-1.1%), BLS 15.7% vs 14.3% (+1.4%)
Risk Factors
- • Litigation risk from 2019 AMCA data breach involving patient info, triggering ongoing regulatory inquiries and legal threats
- • Cybersecurity vulnerability with ransomware incident in 2018 disrupting Dx IT systems and company-wide operations temporarily
Labcorp FY2024 Key Financial MetricsXBRL
Revenue
$13.0B
▲ +7.0% YoY
Net Income
$746M
▲ +78.5% YoY
Gross Margin
27.9%
▲ +19bp YoY
Operating Margin
8.4%
▲ +239bp YoY
Net Margin
5.7%
▲ +230bp YoY
ROE
9.3%
▲ +396bp YoY
Total Assets
$18.4B
▲ +9.9% YoY
EPS (Diluted)
$8.84
▲ +85.3% YoY
Operating Cash Flow
$1.6B
▲ +19.4% YoY
Source: XBRL data from Labcorp FY2024 10-K filing on SEC EDGAR. All figures in USD.
Other Labcorp Annual Reports
Get deeper insights on Labcorp
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.